Selenium-Rich Yeast Peptide Fraction Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis in Mice by Inhibiting Inflammation via MAPK and NF-κB Signaling Pathways

Int J Mol Sci. 2022 Feb 14;23(4):2112. doi: 10.3390/ijms23042112.

Abstract

Psoriasis, a chronic and immune-mediated inflammatory disease, adversely affects patients' lives. We previously prepared selenium-rich yeast peptide fraction (SeP) from selenium-rich yeast protein hydrolysate and found that SeP could effectively alleviate ultraviolet radiation-induced skin damage in mice and inhibited H2O2-induced cytotoxicity in cultured human epidermal keratinocyte (HaCaT) cells. This study aimed to investigate whether SeP had a protective effect on imiquimod (IMQ)-induced psoriasis-like dermatitis in mice and the underlying mechanisms. Results showed that SeP significantly ameliorated the severity of skin lesion in IMQ-induced psoriasis-like mouse model. Moreover, SeP treatment significantly attenuated the expression of key inflammatory cytokines, including interleukin (IL)-23, IL-17A, and IL-17F, in the dorsal skin of mice. Mechanistically, SeP application not only inhibited the activation of JNK and p38 MAPK, but also the translocation of NF-κB into the nucleus in the dorsal skin. Furthermore, SeP treatment inhibited the levels of inflammatory cytokines and the activation of MAPK and NF-κB signaling induced by lipopolysaccharide in HaCaT cells and macrophage cell line RAW264.7. Overall, our findings showed that SeP alleviated psoriasis-like skin inflammation by inhibiting MAPK and NF-κB signaling pathways, which suggested that SeP would have a potential therapeutic effect against psoriasis.

Keywords: MAPK; NF-κB; inflammation; psoriasis; selenium-rich yeast peptide fraction.

MeSH terms

  • Animals
  • Cell Line
  • Dermatitis / drug therapy*
  • Dermatitis / metabolism
  • Disease Models, Animal
  • Female
  • Humans
  • Hydrogen Peroxide / pharmacology
  • Imiquimod / pharmacology
  • Inflammation / drug therapy*
  • Inflammation / metabolism
  • Interleukin-17 / metabolism
  • Keratinocytes / drug effects
  • Keratinocytes / metabolism
  • Mice
  • Mice, Inbred BALB C
  • NF-kappa B / metabolism
  • Peptides / pharmacology*
  • Psoriasis / chemically induced
  • Psoriasis / drug therapy*
  • Psoriasis / metabolism
  • RAW 264.7 Cells
  • Selenium / pharmacology*
  • Signal Transduction / drug effects*
  • Skin / drug effects
  • Skin / metabolism
  • Yeasts / metabolism*

Substances

  • Interleukin-17
  • NF-kappa B
  • Peptides
  • Hydrogen Peroxide
  • Selenium
  • Imiquimod